Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models
January 11th 2018

Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models

Involving providers in the development process of new reimbursement models increases the chance that the initiative will be successful and works against caregiver burnout, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.
AstraZeneca's Osimertinib on Track for First-Line Treatment of NSCLC With a Specific Mutation
January 11th 2018

AstraZeneca's Osimertinib on Track for First-Line Treatment of NSCLC With a Specific Mutation

Allison Inserro
AstraZeneca’s epidermal growth factor receptor (EGFR) inhibitor, osimertinib (Tagrisso), is on the fast track in 2018 to become a first-line treatment for adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations.
Lenvatinib, Pembrolizumab Combination Therapy for Patients With RCC Granted Breakthrough Therapy Designation
January 11th 2018

Lenvatinib, Pembrolizumab Combination Therapy for Patients With RCC Granted Breakthrough Therapy Designation

Jaime Rosenberg
Eisai’s multiple receptor tyrosine kinase inhibitor lenvatinib and Merck’s anti–PD-1 therapy pembrolizumab as a combination therapy for patients with renal cell carcinoma received the designation based on results from the renal cell carcinoma cohort in Study 111.
Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM
January 10th 2018

Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM

Don’t underestimate the power that it takes to make sure a value-based program is working, said Sarah Cevallos, chief revenue cycle officer, Florida Cancer Specialists.
Site Logo
January 9th 2018

US Cancer Mortality Rates Continue to Drop, According to New Report

Jaime Rosenberg
A report from the American Cancer Society estimated new cancer cases and deaths for 2018 and took a look at the most recent data to determine cancer incidence through 2014 and mortality through 2015.
Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM
January 9th 2018

Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM

The healthcare triangle (patients, payers, and providers) begins with the patient, so we should include the patient in some of the decision-making, said Roger Brito, DO, national director for oncology, Aetna.
FDA Approves Denosumab for Prevention of Skeletal-Related Events in Patients with Multiple Myeloma
January 9th 2018

FDA Approves Denosumab for Prevention of Skeletal-Related Events in Patients with Multiple Myeloma

Jaime Rosenberg
The approval will expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to also include patients with multiple myeloma.
Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib
January 7th 2018

Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib

AJMC Staff
A subset of patients with chronic lymphocytic leukemia (CLL) with highly expressed CD49d have poorer outcomes while on Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B-cell receptor (BCR) signals. However, a team of researchers may have found a way to treat these patients.
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 7th 2018

Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care

The fact that you have certain drugs that treat numerous cancers, and that they may treat 1 cancer different or better than another, would suggest that we should probably have differential pricing models, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
Study Examines Cost-Effectiveness in Multiple Myeloma Treatments
January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

Kaitlynn Ely
New drugs to treat multiple myeloma (MM) have provided clinical benefits, but a study published in the Journal of Managed Care & Specialty Pharmacy found not all of them can be considered cost effective.
Study Examines Cost-Effectiveness in Multiple Myeloma Treatments
January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

Kaitlynn Ely
New drugs to treat multiple myeloma (MM) have provided clinical benefits, but a study published in the Journal of Managed Care & Specialty Pharmacy found not all of them can be considered cost effective.
Patients With Small-Cell Lung Cancer Face Barriers to Combined-Modality Therapy
January 5th 2018

Patients With Small-Cell Lung Cancer Face Barriers to Combined-Modality Therapy

Jaime Rosenberg
While chemotherapy with thoracic radiation has been established as the standard of care for the initial treatment of non-metastatic small-cell lung cancer, a large proportion of patients do not receive these treatments and in turn have lower overall survival, according to a study published in JAMA Oncology.
AJMC® in the Press, January 5, 2018
January 5th 2018

AJMC® in the Press, January 5, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Bo Gamble on COA's Role in 2018
January 5th 2018

Bo Gamble on COA's Role in 2018

Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), believes that broadening communication and education is COA’s main goal in 2018.
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 4th 2018

Judy Berger on What Southwest Airlines Is Doing in Oncology

Southwest Airlines has set up a split fill program, pharmacy benefit manager, health advocacy program, and a cancer resource guide for employees, said Judy Berger, senior manager, benefits planning, Southwest Airlines.
Judge Dismisses Challenge to 340B Cuts, Final Rule Goes Into Effect
January 4th 2018

Judge Dismisses Challenge to 340B Cuts, Final Rule Goes Into Effect

Jaime Rosenberg
A federal judge dismissed a move to block 340B cuts days before CMS’ final rule on it went into effect.
Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib
January 4th 2018

Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib

Jaime Rosenberg
Carfilzomib was associated with higher rates of all-grade and high-grade cardiovascular adverse events (CVAE), and both later trial phase and higher doses of carfilzomib were associated with higher rates of CVAE, according to a study in JAMA Oncology.
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
January 3rd 2018

Terrill Jordan Discusses Making Refinements in Year 2 of OCM

Year 2 of the Oncology Care Model is about learning from the lessons of year 1 and extending implementation that has already been started, said Terrill Jordan, CEO of Regional Cancer Care Associates.
Serum Protein Signature Predicts Survival in Patients With Melanoma Receiving Anti–PD-1 Therapy
January 3rd 2018

Serum Protein Signature Predicts Survival in Patients With Melanoma Receiving Anti–PD-1 Therapy

Jaime Rosenberg
A pre-treatment signature of proteins used to predict survival in patients with metastatic melanoma receiving PD-1 inhibitors found that patients deemed sensitive by the test demonstrated significantly better overall survival.
Site Logo
January 1st 2018

How Value Frameworks Define Durable Survival of New Immuno-Oncology Agents

Laura Joszt, MA
New immuno-oncology agents are providing durable survival for some patients, but the cost of these treatments is very high, which is a cause for concern. In a new study in JAMA Oncology, researchers sought to assess how value frameworks defined the efficacy of new immuno-oncology agents.
Smokers Willing to Try E-Cigarettes More Successful at Smoking Less, Study Says
December 31st 2017

Smokers Willing to Try E-Cigarettes More Successful at Smoking Less, Study Says

Allison Inserro
A small pilot study from the Hollings Cancer Center at the Medical University of South Carolina found that smokers who are willing to use e-cigarettes tend to smoke less and have increased quit attempts.
Site Logo
December 29th 2017

The Impact High OOP Costs Have on Patients Filling Prescriptions for Oral Cancer Drugs

Laura Joszt, MA
Patients with cancer may have more options for oral cancer medications, but high out-of-pocket costs still present a barrier to access, according to a new study in Journal of Clinical Oncology.
This Week in Managed Care: December 29, 2017
December 29th 2017

This Week in Managed Care: December 29, 2017

This week, the top managed care stories included a road map to develop state-level programs to care for complex populations; the Physician-focused Payment Technical Advisory Committee backed 2 new alternative payment models; a new cancer gene profiling test may open doors to new targeted therapies.
Top 2017 Articles in AJMC®'s Evidence-Based OncologyTM
December 29th 2017

Top 2017 Articles in AJMC®'s Evidence-Based OncologyTM

Surabhi Dangi-Garimella, PhD
A look at the most popular articles published in Evidence-Based Oncology™ in 2017.
Dr Amy Abernethy Discusses Community Oncologists' Role in Modernizing Evidence Generation
December 27th 2017

Dr Amy Abernethy Discusses Community Oncologists' Role in Modernizing Evidence Generation

Community oncologists have a major role in accelerating treatment development and providing them to patients, said Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies
December 27th 2017

Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies

Jaime Rosenberg
While FoundationOne CDx, the comprehensive companion diagnostic test for solid tumors, gives patients the ability to be accurately matched with a targeted therapy, it also has potential benefits for patients with a less common types of cancers, said Stuart Goldberg, MD, chief scientific officer, Cota, in an interview with The American Journal of Managed Care®.
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26th 2017

Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate

Until more data is available, it’s difficult for a practice or physician group to make an accurate assessment of whether or not 2-sided risk is appropriate, said Sarah Cevallos, chief revenue cycle officer, Florida Cancer Specialists. Physicians would need to see clear metrics in order to know if they will be achievable.
The Role of Oncologists in Moving to Value-Based Care: Torrie Fields Interviews Dr Michael Kolodziej
December 25th 2017

The Role of Oncologists in Moving to Value-Based Care: Torrie Fields Interviews Dr Michael Kolodziej

In this interview, recorded at the end of the first day of PCOC®, Torrie Fields, senior program manager at Blue Shield of California, and Michael Kolodziej, MD, of ADVI Health, discuss the move to value-based care in oncology, what practices need to do to be successful, and the role of team-based care.
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25th 2017

Dr Shannon Maude Discusses Side Effects of CAR T Therapies

Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
Podcast: This Week in Managed Care—Individual Mandate Eliminated and Other Health News
December 23rd 2017

Podcast: This Week in Managed Care—Individual Mandate Eliminated and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
<1
...
596061626364656667
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo